Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib

Mitchell, Catherine C.; Parikh, Omi

doi:10.2147/ppa.s38989

Cited by 4 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the PISCES study (a patient preference study), HRQoL was evaluated using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale: pazopanib obtained a 2.5-point higher score than sunitinib (95% CI: 0.92–4.07; p < 0.002). The Supplementary Quality of Life Questionnaire (SQLQ) questionnaire also showed better results with pazopanib in 5 parameters [ 37 , 38 ]. Finally, in a post-hoc analysis, a trend towards a lower risk of experiencing a > 20% loss of QoL was observed with pazopanib compared to placebo [ 39 ].…”

Section: Resultsmentioning

confidence: 99%

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Mendez-Vidal

Molina

Anido

et al. 2018

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

BackgroundPazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice.MethodsA non-exhaustive systematic review was conducted according to the three topics. No publication restrictions were imposed and the selected languages were Spanish and English. After that, a summary of the main results and findings of the review was presented and discussed during three meetings (one for each topic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of pazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist medical oncologists in renal cancer.ResultsThe efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently confirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of life results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of patients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly patients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with concomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an effective drug, in which quality of life (QoL) outcomes are valued above all.ConclusionsThis paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of pazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and tolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to be safe in different patient profiles.

show abstract

Section: Resultsmentioning

confidence: 99%

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Mendez-Vidal

Molina

Anido

et al. 2018

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

show abstract

Triggering of Suicidal Erythrocyte Death by Pazopanib

Signoretto

Zierle²,

Bissinger³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The multi-targeted kinase inhibitor pazopanib, a drug employed for the treatment of a wide variety of malignancies, has previously been shown to trigger apoptosis. Similar to apoptosis of nucleated cells, erythrocytes may enter suicidal death or eryptosis, characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the erythrocyte surface. Mechanisms involved in the triggering of eryptosis include Ca²⁺ entry, oxidative stress and ceramide. The present study explored, whether pazopanib induces eryptosis and, if so, whether it is effective by Ca²⁺ entry, oxidative stress and/or ceramide. Methods: Phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, reactive oxygen species (ROS) formation from DCF dependent fluorescence, and ceramide abundance utilizing specific antibodies. Results: A 48 hours exposure of human erythrocytes to pazopanib significantly increased the percentage of annexin-V-binding (≥ 25 µg/ml) and of shrunken erythrocytes (≥ 50 µg/ml). Pazopanib treatment further resulted in significant hemolysis (≥ 25 µg/ml). The effect of pazopanib on annexin-V-binding was significantly blunted but not abolished by removal of extracellular Ca²⁺. Pazopanib significantly increased DCF fluorescence (50 µg/ml) and ceramide abundance (50 µg/ml). Conclusions: Pazopanib triggers eryptosis, an effect involving Ca²⁺ entry, oxidative stress and ceramide.

show abstract

Pazopanib in the treatment of advanced renal cell carcinoma

Cella

Beaumont

2015

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Pazopanib is an orally available multitargeted tyrosine kinase inhibitor (a class of targeted therapies) that inhibits tumor angiogenesis and cell proliferation. The safety and efficacy of pazopanib (noninferior to sunitinib for progression-free survival) in patients with advanced or metastatic renal cell carcinoma (mRCC) have been demonstrated in several clinical trials. However, in addition to therapeutic efficacy, treatment choices should also take into account health-related quality of life (HRQoL) aspects of cancer therapy. Here, we summarize the HRQoL findings related to pazopanib use, based on patient-reported outcome measures; pazopanib has been shown to be superior to sunitinib on several HRQoL domains (including patient preference). A further consideration for treatment choice is how well the findings from clinical trials correlate with evidence from general clinical practice. This review therefore includes descriptions of real-world experience of pazopanib use in the treatment of patients with mRCC, following its approval by medical regulatory authorities in a number of countries. Naturalistic observational studies demonstrate that the efficacy of pazopanib in patients with mRCC is consistent with clinical trial findings. Similarly, consistent results were observed for the safety profile of pazopanib between observational studies and clinical trials, with most treatment-associated adverse events being mild to moderate in severity, and manageable.

show abstract

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib

Cited by 4 publications

References 34 publications

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Triggering of Suicidal Erythrocyte Death by Pazopanib

Pazopanib in the treatment of advanced renal cell carcinoma

Contact Info

Product

Resources

About